DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

DE

470.26

-1.59%↓

FDX

245.41

+1.56%↑

PAYX

155.09

+0.39%↑

CPRT

57.56

+0.61%↑

HEICA

212.9

+0.18%↑

Search

Ocugen Inc

Închisă

0.68 6.25

Rezumat

Modificarea prețului

24h

Curent

Minim

0.62

Maxim

0.7

Indicatori cheie

By Trading Economics

Venit

-910K

-14M

Vânzări

-372K

764K

EPS

-0.05

Marjă de profit

-1,816.754

Angajați

95

EBITDA

-603K

-13M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+926.15% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

57M

233M

Deschiderea anterioară

-5.57

Închiderea anterioară

0.68

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

8 apr. 2024, 14:32 UTC

Principalele dinamici ale pieței

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

926.15% sus

Prognoză pe 12 luni

Medie 6.67 USD  926.15%

Maxim 8 USD

Minim 4 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.6351 / 0.7995Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.